MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

Home・Aandelen Lijst・Design Therapeutics Inc

Design Therapeutics Inc

Open

12.69 0.87

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

12.41

Max

12.9

Belangrijke statistieken
By Trading Economics
Inkomsten	1M -16M
Werknemers	54
EBITDA	-1.2M -18M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+22.63% upside

Dividenden
By Dow Jones
Volgende Winsten	5 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	179M 762M
Vorige openingsprijs	11.82
Vorige sluitingsprijs	12.69

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

3.26 / 3.63 Steun & Weerstand

Design Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 apr 2026, 23:36 UTC

Acquisities, Fusies, Overnames

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion -- Update

14 apr 2026, 23:24 UTC

Populaire aandelen

Stocks to Watch: Gloo, Broadcom, GitLab

14 apr 2026, 22:42 UTC

Acquisities, Fusies, Overnames

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion

14 apr 2026, 21:32 UTC

Belangrijke Marktbewegers

GitLab Shares Rise on Expanded Google Cloud Collaboration

14 apr 2026, 23:54 UTC

Marktinformatie

Nikkei May Rise as Fears About Energy Shortage Ease -- Market Talk

14 apr 2026, 23:34 UTC

Marktinformatie

Gold Edges Lower on Possible Technical Correction -- Market Talk

14 apr 2026, 22:54 UTC

Winsten

BRP: Amendment Mainly Leads to 25% Tariff on Total Value of Imported Snowmobiles and Majority of ORV Models, Replacing Previous 50% Tariff on Applicable Metal Content Only >DOO.T

14 apr 2026, 22:54 UTC

Winsten

BRP: Suspending Guidance Following Amendment of Section 232 Tariffs on Steel, Aluminum and Copper Imports Into U.S., Which Came Into Effect on April 6 >DOO.T

14 apr 2026, 22:54 UTC

Winsten

BRP: Currently Estimates Potential Incremental Tariff Cost Related to This Amendment in Excess of $500M for Remainder of Yr >DOO.T

14 apr 2026, 22:54 UTC

Winsten

BRP: Suspends FY27 Guidance Due to Changes to U.S. Tariff Environment

14 apr 2026, 22:17 UTC

Acquisities, Fusies, Overnames

Yancoal Australia: Targets Deal Completion Toward End of 3Q

14 apr 2026, 22:17 UTC

Acquisities, Fusies, Overnames

Yancoal Australia: Acquisition Diversifies Portfolio; Met Coal Share to Rise to 22%

14 apr 2026, 22:17 UTC

Acquisities, Fusies, Overnames

Yancoal Australia: Asset 'Strong Strategic Fit'; to Positively Add Production, Cash Flow

14 apr 2026, 22:16 UTC

Acquisities, Fusies, Overnames

Yancoal Australia: Intends to Fund Acquisition With Cash, 5-Year Loan Facility

14 apr 2026, 22:15 UTC

Acquisities, Fusies, Overnames

Yancoal Australia: Contingent Consideration Linked to Average Annual Prices For 5 Years

14 apr 2026, 22:14 UTC

Acquisities, Fusies, Overnames

Yancoal Australia: Deal Includes Contingent Cash Consideration Up to $550 Million

14 apr 2026, 22:13 UTC

Acquisities, Fusies, Overnames

Yancoal Australia: Deal Includes $1.85 Billion Upfront Consideration

14 apr 2026, 22:12 UTC

Acquisities, Fusies, Overnames

Yancoal Australia: To Buy Kestrel Stake From EMR Capital, Adaro Capital

14 apr 2026, 22:12 UTC

Acquisities, Fusies, Overnames

Yancoal Australia: To Buy Kestrel Stake For Up to $2.4 Billion

14 apr 2026, 22:10 UTC

Acquisities, Fusies, Overnames

Yancoal Australia: to Acquire 80% Interest in Kestrel Coal Mine

14 apr 2026, 20:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

14 apr 2026, 20:33 UTC

Acquisities, Fusies, Overnames

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14 apr 2026, 20:32 UTC

Populaire aandelen

Stocks to Watch: JPMorgan, American Airlines, LVMH, BlackRock -- WSJ

14 apr 2026, 19:59 UTC

Acquisities, Fusies, Overnames

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14 apr 2026, 19:38 UTC

Winsten

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 apr 2026, 19:27 UTC

Marktinformatie

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

14 apr 2026, 19:21 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Futures Retreat on Hopes for U.S.-Iran Peace Talks -- Market Talk

14 apr 2026, 19:09 UTC

Acquisities, Fusies, Overnames

Apple and Amazon Partner on Satellite Deal. Why It Makes Sense. -- Barrons.com

14 apr 2026, 18:30 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

14 apr 2026, 18:30 UTC

Marktinformatie

Treasury Yields, Dollar Fall as Markets Price Higher Odds of Fed Cuts -- Market Talk

Peer Vergelijking

Prijswijziging

Design Therapeutics Inc Prognose

Koersdoel

By TipRanks

22.63% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 15.5 USD 22.63%

Hoogste 18 USD

Laagste 14 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Design Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Design Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

3.26 / 3.63Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.